Kendall Investor Relations Leadership

Kendall Investor Relations is a biotech-focused firm advising on investor strategy, positioning, and execution across private and public financings. We help companies define a differentiated investment narrative aligned with how healthcare investors evaluate risk, data, and value.

​

Our team consists of former biotech executives with experience across R&D, clinical development, corporate development, commercialization, finance, and investor relations. We bring an operator’s perspective, with direct experience supporting IPO preparation, crossover and follow-on financings, and clinical data readouts.

 

We translate complex science into a clear, investable equity story and support the full financing lifecycle—from narrative development and investor targeting through execution, including S-1 positioning and preparation for investor diligence.

​

Our experience and relationships within the biotech investment community enable effective engagement with crossover and public market investors, supporting capital formation and long-term value creation.